Floatz logo

Donanemab

Central Nervous System Diseases

Eli Lilly and Companymonoclonal_antibodyPhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

21 Active assets in the Central Nervous System Diseases cohort.

Asset / SponsorPhaseRating
3-N-BUTYLPHTHALIDE
Qianfoshan Hospital
Phase 4BB
Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules
Beijing Friendship Hospital
Phase 4BB
Live Combined Bifidobacterium
Beijing Friendship Hospital
Phase 4BB
ENCENICLINE
FORUM Pharmaceuticals Inc
Phase 2BB
LEVODOPA
Merck Sharp & Dohme LLC
Phase 2B

View all 50 →

Same molecule, other indications

Donanemab is also rated in:

Alzheimer diseaseDormant
BB
Indicative ·
70 / 100
View asset →
Down syndromeDormant
BB
Indicative ·
65 / 100
View asset →
APP-related brain and vascular amyloidosisDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →